236 related articles for article (PubMed ID: 32039480)
21. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
23. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
Aziz MD; Shah J; Kapoor U; Dimopoulos C; Anand S; Augustine A; Ayuk F; Chaudhry M; Chen YB; Choe HK; Etra A; Gergoudis S; Hartwell MJ; Hexner EO; Hogan WJ; Kitko CL; Kowalyk S; Kröger N; Merli P; Morales G; Nakamura R; Ordemann R; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Schreiner E; Srinagesh H; Wölfl M; Wudhikarn K; Yanik G; Young R; Özbek U; Ferrara JLM; Levine JE
Leukemia; 2020 Jul; 34(7):1898-1906. PubMed ID: 32020045
[TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Liu S; Han J; Gong H; Li Y; Bao X; Qi J; Liu H; Chen J; Wu X; Xu Y; Ma S; Wu D
Sci Rep; 2018 Jul; 8(1):10328. PubMed ID: 29985424
[TBL] [Abstract][Full Text] [Related]
25. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
26. Advances in predicting acute GVHD.
Harris AC; Ferrara JL; Levine JE
Br J Haematol; 2013 Feb; 160(3):288-302. PubMed ID: 23205489
[TBL] [Abstract][Full Text] [Related]
27. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
28. Discovery and validation of graft-versus-host disease biomarkers.
Paczesny S
Blood; 2013 Jan; 121(4):585-94. PubMed ID: 23165480
[TBL] [Abstract][Full Text] [Related]
29. Changes in protein serum levels during stem cell transplantation.
Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
[TBL] [Abstract][Full Text] [Related]
30. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of biomarkers associated with acute and chronic graft versus host disease.
Ahmed SS; Wang XN; Norden J; Pearce K; El-Gezawy E; Atarod S; Hromadnikova I; Collin M; Holler E; Dickinson AM
Bone Marrow Transplant; 2015 Dec; 50(12):1563-71. PubMed ID: 26367225
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
33. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
35. Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.
Chen S; Zeiser R
Front Immunol; 2020; 11():1854. PubMed ID: 33013836
[TBL] [Abstract][Full Text] [Related]
36. Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study.
Min SS; Mehra V; Clay J; Cross GF; Douiri A; Dew T; Basu TN; Potter V; Ceesay MM; Pagliuca A; Sherwood RA; Vincent RP
J Clin Pathol; 2017 Oct; 70(10):886-890. PubMed ID: 28450387
[TBL] [Abstract][Full Text] [Related]
37. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
[TBL] [Abstract][Full Text] [Related]
38. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
39. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
[TBL] [Abstract][Full Text] [Related]
40. Biomarker Panel for Chronic Graft-Versus-Host Disease.
Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
